Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes
(1) The study evaluated correlations between multi-frequency vibrometry (MF-V) and the measure of chemotherapy-induced peripheral neuropathy developed by the European Organization for the Research and Treatment of Cancer (CIPN18). (2) Patients with cancer scheduled to undergo treatment with capecita...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/7/1862 |
| _version_ | 1797438774187130880 |
|---|---|
| author | Sebastian W. Nielsen Sanne Lindberg Christina Halgaard Bruvik Ruhlmann Lise Eckhoff Jørn Herrstedt |
| author_facet | Sebastian W. Nielsen Sanne Lindberg Christina Halgaard Bruvik Ruhlmann Lise Eckhoff Jørn Herrstedt |
| author_sort | Sebastian W. Nielsen |
| collection | DOAJ |
| description | (1) The study evaluated correlations between multi-frequency vibrometry (MF-V) and the measure of chemotherapy-induced peripheral neuropathy developed by the European Organization for the Research and Treatment of Cancer (CIPN18). (2) Patients with cancer scheduled to undergo treatment with capecitabine and oxaliplatin (CAPOX) or carboplatin and paclitaxel (Carbo-Tax) were recruited in a prospective, observational study with MF-V and the CIPN18 from baseline to one year after end of treatment. (3) The study recruited 31 evaluable patients. All MF-V measurements correlated significantly with the CIPN18 scores (<i>r</i> = 0.25–0.48, <i>p</i> > 0.003), with a low frequency (32 Hz) from metatarsals showing the best correlation coefficients (0.059 Z-score per CIPN18 point change, <i>r</i> = 0.48, CI-95 = [0.32; 0.60], <i>p</i> > 0.0001). The largest change in MF-V scores from baseline was seen in low-frequency VPTs taken from metatarsals at 8 Hz three months after end of treatment (from −0.26, CI-95 [−0.85, 0.38] to 1.15, CI-95 [0.53, 1.84]) for patients treated with oxaliplatin and at 32 Hz one year after end of treatment (from 0.09, CI-95 [−0.56, 0.77] to 0.88, CI-95 [0.34, 1.47]) for patients treated with paclitaxel. (4) Low-frequency vibration perception thresholds (8 and 32 Hz) correlated better with CIPN18 scores than high-frequency ones (128 and 250 Hz). If validated, this finding will advance CIPN pathophysiological understanding and inform the development of assessment methods. |
| first_indexed | 2024-03-09T11:43:09Z |
| format | Article |
| id | doaj.art-0cd53c1f765546518efc69c809ddc633 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T11:43:09Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-0cd53c1f765546518efc69c809ddc6332023-11-30T23:27:55ZengMDPI AGJournal of Clinical Medicine2077-03832022-03-01117186210.3390/jcm11071862Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported OutcomesSebastian W. Nielsen0Sanne Lindberg1Christina Halgaard Bruvik Ruhlmann2Lise Eckhoff3Jørn Herrstedt4Department of Clinical Oncology and Palliative Care, Zealand University Hospital, 4000 Roskilde, DenmarkDepartment of Clinical Oncology and Palliative Care, Zealand University Hospital, 4000 Roskilde, DenmarkDepartment of Clinical Research, University of Southern Denmark, 5000 Odense C, DenmarkDepartment of Oncology R, Odense University Hospital, 5000 Odense C, DenmarkDepartment of Clinical Oncology and Palliative Care, Zealand University Hospital, 4000 Roskilde, Denmark(1) The study evaluated correlations between multi-frequency vibrometry (MF-V) and the measure of chemotherapy-induced peripheral neuropathy developed by the European Organization for the Research and Treatment of Cancer (CIPN18). (2) Patients with cancer scheduled to undergo treatment with capecitabine and oxaliplatin (CAPOX) or carboplatin and paclitaxel (Carbo-Tax) were recruited in a prospective, observational study with MF-V and the CIPN18 from baseline to one year after end of treatment. (3) The study recruited 31 evaluable patients. All MF-V measurements correlated significantly with the CIPN18 scores (<i>r</i> = 0.25–0.48, <i>p</i> > 0.003), with a low frequency (32 Hz) from metatarsals showing the best correlation coefficients (0.059 Z-score per CIPN18 point change, <i>r</i> = 0.48, CI-95 = [0.32; 0.60], <i>p</i> > 0.0001). The largest change in MF-V scores from baseline was seen in low-frequency VPTs taken from metatarsals at 8 Hz three months after end of treatment (from −0.26, CI-95 [−0.85, 0.38] to 1.15, CI-95 [0.53, 1.84]) for patients treated with oxaliplatin and at 32 Hz one year after end of treatment (from 0.09, CI-95 [−0.56, 0.77] to 0.88, CI-95 [0.34, 1.47]) for patients treated with paclitaxel. (4) Low-frequency vibration perception thresholds (8 and 32 Hz) correlated better with CIPN18 scores than high-frequency ones (128 and 250 Hz). If validated, this finding will advance CIPN pathophysiological understanding and inform the development of assessment methods.https://www.mdpi.com/2077-0383/11/7/1862chemotherapy-induced peripheral neuropathyoxaliplatin-induced peripheral neuropathypaclitaxel-induced peripheral neuropathyperipheral neuropathymulti-frequency vibrometry |
| spellingShingle | Sebastian W. Nielsen Sanne Lindberg Christina Halgaard Bruvik Ruhlmann Lise Eckhoff Jørn Herrstedt Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes Journal of Clinical Medicine chemotherapy-induced peripheral neuropathy oxaliplatin-induced peripheral neuropathy paclitaxel-induced peripheral neuropathy peripheral neuropathy multi-frequency vibrometry |
| title | Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes |
| title_full | Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes |
| title_fullStr | Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes |
| title_full_unstemmed | Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes |
| title_short | Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes |
| title_sort | addressing chemotherapy induced peripheral neuropathy using multi frequency vibrometry and patient reported outcomes |
| topic | chemotherapy-induced peripheral neuropathy oxaliplatin-induced peripheral neuropathy paclitaxel-induced peripheral neuropathy peripheral neuropathy multi-frequency vibrometry |
| url | https://www.mdpi.com/2077-0383/11/7/1862 |
| work_keys_str_mv | AT sebastianwnielsen addressingchemotherapyinducedperipheralneuropathyusingmultifrequencyvibrometryandpatientreportedoutcomes AT sannelindberg addressingchemotherapyinducedperipheralneuropathyusingmultifrequencyvibrometryandpatientreportedoutcomes AT christinahalgaardbruvikruhlmann addressingchemotherapyinducedperipheralneuropathyusingmultifrequencyvibrometryandpatientreportedoutcomes AT liseeckhoff addressingchemotherapyinducedperipheralneuropathyusingmultifrequencyvibrometryandpatientreportedoutcomes AT jørnherrstedt addressingchemotherapyinducedperipheralneuropathyusingmultifrequencyvibrometryandpatientreportedoutcomes |